Chimagen Biosciences

Company Deals

GSK Secures Global Rights to Chimagen Biosciences’ T Cell-Engager in $850 Million Deal

Fineline Cube Oct 30, 2024

UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen...

Company Drug

Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis

Policy / Regulatory

China’s National Health Commission Outlines Key Tasks for Primary Healthcare Reform in 2025

Company Drug

Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU

Company Drug Legal / IP

AccurEdit’s ARTbase-A1 Base Editor Authorized by USPTO